Dr. Stacie Dusetzina and Dr. Peter Bach present an analysis of the implications of the Trump Administration’s proposed changes to eliminate Medicare Part D rebates from drug manufacturers, published in JAMA.
Dr. Peter Bach, alongside Kathy Sego, Dr. Douglas Holtz-Eakin, and Dr. Mark Miller, testified before U.S. Senate Finance Committee at its first hearing of the session, Drug Pricing in America: A Prescription for Change, Part I.
Pharmaceutical manufacturers push for adoption of outcomes-based contracting as a means of achieving a value-based price. Drs. Bach and Mailankody argue that outcomes-based contracts are ill-suited to do so.